Psychopharmacopeia.com is a progressive web application aimed at providing clinicians with fast access to psychiatric drug information.
Quickly find indications (including off-label), dosing, side effects, clinically useful pharmacokinetic and pharmacodynamic information, drug-drug interactions, and prescribing pearls for special populations i.e. pregnant, lactating, patients with renal or hepatic impairment, elderly, etc. At last, a virtual Rolodex of psychopharm information, accessible anywhere and across devices.
This site is being updated almost daily. Brexanolone is our most recent addition to the rapidly growing drug database.
Check out our new QT reference page with tables summarizing QT prolongation risk factors, including medication tables for both psych and non-psych meds (with comparison of high vs low risk of QT prolongation of various classes of psych meds).
All drugs in the psychopharm database populate our CYP450 table, organized into substrates, inhibitors, and inducers of the major CYP pathways (1A2, 2D6, 2C9/C19, 3A4).
Converting a patient from one benzodiazepine to another? This benzodiazepine conversion tool shows the equipotent dose of the drug you're converting to, while comparing basic pharmacokinetic and prescribing information side-by-side.
The antipsychotic conversion tool allows for quick calculation of equipotent antipsychotic doses for 20 different antipsychotic medications based on published chlorpromazine equivalents and provides suggested cross-taper schedule for making the switch!
The stimulant dose conversion calculator is still in progress, and so far can convert doses to/from among Ritalin, Adderall, Vyvanse, Dexadrine, and Focalin. Look for updates to this conversion tool soon!
Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders
Posted on Friday November 22, 2019
This systematic review and meta-analysis of 69 randomized clinical trials assesses long-term outcomes after cognitive behavioral therapy for anxiety disorders, posttraumatic stress disorder, and obsessive-compulsive disorder.
Ranking Antipsychotics for Efficacy and Safety in Schizophrenia
Posted on Tuesday November 05, 2019
This Viewpoint examines network meta-analyses that explore the efficacy of various antipsychotics in treating schizophrenia.
Association Between High School Personality Phenotype and Dementia 54 Years Later in a US Sample
Posted on Tuesday October 15, 2019
This national US cohort study examines whether personality during adolescence—a time when preclinical dementia pathology is unlikely to be present—confers risk of dementia in later life and tests whether associations could be accounted for by health factors in adolescence or differed across socioeconomic status.
Shared Neural Phenotypes for Mood and Anxiety Disorders
Posted on Tuesday October 29, 2019
This meta-analysis evaluates the presence of transdiagnostic convergence in abnormalities in task-related brain activation in patients with mood disorders, anxiety disorders, and posttraumatic stress disorder.
Posted on Tuesday October 29, 2019
This narrative review gives an overview of the causative mechanisms of schizophrenia from molecular, genetic, and psychosocial angles.
Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated August 08 2019 14:18:39. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.